Biogen Message Board - Msg: 4952101

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 181.89

0.0%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bwe who wrote (676)	6/21/1998 11:42:00 AM
From: Harold Engstrom	Read Replies (1) of 1686

Thanks for the encouragement and information. I'm never sure if more than a couple of people read this thread or not. I think the $85MM mark is possible this quarter. The slides shown at the meeting clearly showed a drop in momentum at the end of last year and a nice pop back into higher momentum for Avonex sales at the end of last quarter and into this quarter. Jim Tobin did say they were closing in on 45,000 patients and I thought the number was 38,000 at the end of last quarter (but could be wrong on that). The side-effect profile is still far superior to that of competing therapies and Biogen's data is still the only data to pass rigorous scrutiny and prove that Avonex slows MS progression. There is currently a 2ndary progressive trial that the company said should be complete in 2000. The company is hopeful that they can widen the market significantly earlier. Furthermore, the company is convinced that one or more of its other products in its anti-inflammatory program will be the next big leap in treating MS. PuddleGlum, this is the Yin to my IDTI Yang.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next